Revised SPC: Tecentriq (atezolizumab) concentrate for solution for infusion

SPC updated with licence extension for use as first line monotherapy for metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression ≥ 50% tumour cells or ≥ 10% tumour-infiltrating immune cells and who do not have EGFR+ve or ALK+ve NSCLC.

Source:

electronic Medicines compendium